Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentations

Poster: ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease
November 13th, 2025
Poster: Preclinical Development of ST-503: an Investigational Adeno-associated Viral Vector Delivered Zinc Finger Repressor Novel Epigenetic Therapy for Idiopathic Small Fiber Neuropathy
September 10th, 2025
Poster: Isaralgagene Civaparvovec (ST-920) Shows Positive Mean Annualized eGFR Slope in Adults with Fabry Disease: Updated Results from the Registrational Phase 1/2 STAAR Gene Therapy Study
September 6th, 2025
Presentation: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
February 10th, 2025
Poster: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
February 10th, 2025
Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Primary Analysis Results From the Phase 3 AFFINE Gene Therapy Trial
December 10th, 2024
Presentation: Single Intravenous Treatment with Zinc Finger Repressor Leads to Brainwide Reduction of Prion in Nonhuman Primates and Significantly Prolongs Survival in the RML Mouse Model
December 1st, 2024
Presentation: A Highly Potent Engineered AAV Capsid, STAC-150, Enables High-Throughput AAV Production and Arrayed Epigenetic Regulator Screening Directly in Cultured Neurons
May 10th, 2024
Presentation: Directed Evolution of Bxb1 for the Development of Modular Integrases (MINTS)
May 9th, 2024
Presentation: Identification and Characterization of STAC-BBB, an Engineered AAV Capsid That Exhibits Widespread Transduction of the Central Nervous System in Cynomolgus Macaques
May 9th, 2024